Kymera Therapeutics, Inc. Common Stock
$117.75
-$0.73 (-0.62%)
$116.36Day Range$119.06
Key Statistics
Market Cap
$9.79B
Shares Outstanding
83.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 21, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$119.06
Day High
$119.06
Day Low
$116.36
Volume
1.90M
VWAP
$117.72
Prev Close
$118.48
Transactions
--
Acc. Volume
--
About Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836273 employees500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472857-285-5314IPO Aug 21, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001815442
- Composite FIGI
- BBG00SDHC8D1
- Share Class FIGI
- BBG00SDHC8F9
- Ticker Root
- KYMR
- SIC Code
- 2836
About Kymera Therapeutics, Inc. Common Stock (KYMR) Stock
Kymera Therapeutics, Inc. Common Stock (KYMR) closed the 2026-09-18 session at $117.75, down 0.62% versus the previous close (-0.73). The stock opened at $119.06 and traded between $116.36 and $119.06 during that session. Session trading volume was 1.9M shares. The volume-weighted average price (VWAP) is $117.72.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Kymera Therapeutics, Inc. Common Stock has a market capitalization of $9.79 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. KYMR is listed on the XNAS exchange. The company employs approximately 273 people. Kymera Therapeutics, Inc. Common Stock is headquartered in WATERTOWN, MA. The recorded listing date is 2020-08-21.
On this page you can find market KYMR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.